Regis P Radermecker

Summary

Country: Belgium

Publications

  1. ncbi [How I treat...severe hypoglycemia in a diabetic patient]
    R P Radermecker
    , , , ,
    Rev Med Liege 58:119-22. 2003
  2. ncbi Allergy reactions to insulin: effects of continuous subcutaneous insulin infusion and insulin analogues
    R P Radermecker
    Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman, University of Liege, B 4000 Liege, Belgium
    Diabetes Metab Res Rev 23:348-55. 2007
  3. ncbi [Effects of glimepiride (Amarylle) in type 2 diabetic patients: results of the Belgian study RECORD in general medicine]
    R P Radermecker
    Service de Diabetologie, Nutrition et Maladies Metaboliques, CHU Sart Tilman, Liege
    Rev Med Liege 61:423-9. 2006
  4. ncbi [Risk of hypoglycaemia: therapeutical implications]
    R P Radermecker
    Service de Diabetologie, Nutrition et Maladies Metaboliques, CHU Sart Tilman, 4000 Liege, Belgique
    Rev Med Liege 60:461-5. 2005
  5. ncbi [Distinction between good synthesizer and good absorber patients to optimize cholesterol-lowering therapy]
    R P Radermecker
    Université de Liège Service de diabétologie, Nutrition et Maladies Metaboliques, CHU SartTilman, B 4000 Liege I
    Rev Med Suisse 2:1910-5. 2006
  6. ncbi [Role of insulin secretagogues in the treatment of type 2 diabetes]
    R P Radermecker
    Service de Diabetologie, Nutrition et Maladies Metaboliques, Departement de Medecine, CHU Sart Tilman
    Rev Med Liege 60:402-8. 2005
  7. ncbi [Inhaled insulin, new perspective for insulin therapy]
    R P Radermecker
    Service de Diabetologie, Nutrition et Maladies Metaboliques, CHU Sart Tilman, 4000 Liege, Belgique
    Rev Med Liege 60:355-60. 2005
  8. ncbi [Continuous subcutaneous insulin infusion with portable pumps]
    R P Radermecker
    Universite de Liege, Service de Diabetologie, Nutrition et Maladies Metaboliques, Departement de Medecine, CHU Sart Tilman
    Rev Med Liege 60:329-34. 2005
  9. ncbi Lipodystrophy reactions to insulin: effects of continuous insulin infusion and new insulin analogs
    Regis P Radermecker
    Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, University Hospital Sart Tilman, University of Liege, Liege, Belgium
    Am J Clin Dermatol 8:21-8. 2007
  10. ncbi [Brain, a gluco-dependent organ: toxic effects of hypoglycaemia and hyperglycaemia]
    R R Radermecker
    Universite de Liege, Service de Diabetologie, Nutrition et Maladies Metaboliques, Departement de Medecine, CHU Sart Tilman, Liege, Belgique
    Rev Med Liege 63:280-6. 2008

Collaborators

Detail Information

Publications33

  1. ncbi [How I treat...severe hypoglycemia in a diabetic patient]
    R P Radermecker
    , , , ,
    Rev Med Liege 58:119-22. 2003
    ....
  2. ncbi Allergy reactions to insulin: effects of continuous subcutaneous insulin infusion and insulin analogues
    R P Radermecker
    Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman, University of Liege, B 4000 Liege, Belgium
    Diabetes Metab Res Rev 23:348-55. 2007
    ..Finally, data on antigenicity and immunogenicity of long-acting insulin analogues (glargine, detemir), which may mimic the basal insulin delivery with CSII, remain scarce at present...
  3. ncbi [Effects of glimepiride (Amarylle) in type 2 diabetic patients: results of the Belgian study RECORD in general medicine]
    R P Radermecker
    Service de Diabetologie, Nutrition et Maladies Metaboliques, CHU Sart Tilman, Liege
    Rev Med Liege 61:423-9. 2006
    ..The value of such a study is to provide valuable information about glimepiride use in real life, a condition that may differ from strict follow-up imposed in randomised controlled clinical trials...
  4. ncbi [Risk of hypoglycaemia: therapeutical implications]
    R P Radermecker
    Service de Diabetologie, Nutrition et Maladies Metaboliques, CHU Sart Tilman, 4000 Liege, Belgique
    Rev Med Liege 60:461-5. 2005
    ..The present paper briefly describes some clinical situations increasing the risk of hypoglycaemia in diabetic patients treated with insulin or insulin secreting agents, emphasizing upon important therapeutic implications...
  5. ncbi [Distinction between good synthesizer and good absorber patients to optimize cholesterol-lowering therapy]
    R P Radermecker
    Université de Liège Service de diabétologie, Nutrition et Maladies Metaboliques, CHU SartTilman, B 4000 Liege I
    Rev Med Suisse 2:1910-5. 2006
    ..They may benefit of an adjunct therapy with phytostanols or ezetimibe, both being capable to reduce plasma concentrations of cholesterol and of phytosterols...
  6. ncbi [Role of insulin secretagogues in the treatment of type 2 diabetes]
    R P Radermecker
    Service de Diabetologie, Nutrition et Maladies Metaboliques, Departement de Medecine, CHU Sart Tilman
    Rev Med Liege 60:402-8. 2005
    ..The metabolic effects of glucagon-like peptide-1 (GLP-1) appear very promising, and can be either reproduced by long-acting GLP-1 analogues, or enhanced by inhibitors of dipeptidylpeptidase-IV, an enzyme that destroys GLP-1...
  7. ncbi [Inhaled insulin, new perspective for insulin therapy]
    R P Radermecker
    Service de Diabetologie, Nutrition et Maladies Metaboliques, CHU Sart Tilman, 4000 Liege, Belgique
    Rev Med Liege 60:355-60. 2005
    ..Nevertheless, inhaled insulin is an attractive topic in which most important pharmaceutical companies are currently involved...
  8. ncbi [Continuous subcutaneous insulin infusion with portable pumps]
    R P Radermecker
    Universite de Liege, Service de Diabetologie, Nutrition et Maladies Metaboliques, Departement de Medecine, CHU Sart Tilman
    Rev Med Liege 60:329-34. 2005
    ..The present paper describes recommendations, advantages and limits as well as cost of CSII with portable pumps in type 1 diabetic patients...
  9. ncbi Lipodystrophy reactions to insulin: effects of continuous insulin infusion and new insulin analogs
    Regis P Radermecker
    Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, University Hospital Sart Tilman, University of Liege, Liege, Belgium
    Am J Clin Dermatol 8:21-8. 2007
    ..Conversely, exceptional cases of lipoatrophy have occurred in patients receiving lispro insulin analog via CSII. Lipodystrophy reactions remain a potential problem when managing diabetic patients with new insulin therapy technologies...
  10. ncbi [Brain, a gluco-dependent organ: toxic effects of hypoglycaemia and hyperglycaemia]
    R R Radermecker
    Universite de Liege, Service de Diabetologie, Nutrition et Maladies Metaboliques, Departement de Medecine, CHU Sart Tilman, Liege, Belgique
    Rev Med Liege 63:280-6. 2008
    ..The present paper summarizes the current knowledge of both acute and chronic cerebral dysfunctions following perturbations of blood glucose levels in diabetic patients...
  11. ncbi [Biphasic insulin aspart (NovoMix 50)]
    R P Radermecker
    Universite de Liege, Service de Diabetologie, Nutrition et Maladies métaboliques et Unité de Pharmacologie clinique, Departement de Medecine, CHU de Liege, Belgique
    Rev Med Liege 63:688-92. 2008
    ....
  12. ncbi Continuous glucose monitoring as a tool to identify hyperglycaemia in non-diabetic patients with acute coronary syndromes
    R P Radermecker
    Endocrinology Department, CHU Montpellier, Universite Montpellier, Montpellier, France
    Diabet Med 26:167-70. 2009
    ..To explore the occurrence and the distribution of glucose excursions > 7.8 mmol/l by continuous glucose monitoring (CGM) in non-diabetic patients admitted with acute coronary syndrome (ACS)...
  13. ncbi Circulating insulin antibodies: influence of continuous subcutaneous or intraperitoneal insulin infusion, and impact on glucose control
    R P Radermecker
    Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Liege, University of Liege, Liege, Belgium
    Diabetes Metab Res Rev 25:491-501. 2009
    ....
  14. ncbi [Field, a randomized clinical trial of cardiovascular prevention with fenofibrate in type 2 diabetes]
    R P Radermecker
    Departement de Medecine, CHU Sart Tilman, 4000 Liege
    Rev Med Liege 60:957-61. 2005
    ..More surprisingly, fenofibrate exerted a favourable effect on microangiopathy complications, with less albuminuria progression and less retinopathy needing laser treatment (tertiary endpoints)...
  15. ncbi [Insulin therapy in type 1 diabetes]
    J C Philips
    , , ,
    Rev Med Liege 60:322-8. 2005
    ..Functional insulin therapy may be part of this strategy...
  16. ncbi [Optimizing the managment of patients with diabetes mellitus: selected clinical trials from the 2004 Congress of the American Diabetes Association]
    A J Scheen
    , , , CHU Sart Tilman,
    Rev Med Liege 59:407-12. 2004
    ..The main results and conclusions of these trials are briefly presented as they open new perspectives in the management of patients with type 1 or type 2 diabetes mellitus...
  17. ncbi [Insulin detemir (Levemir)]
    A J Scheen
    Service de Diabetologie, Nutrition et Maladies Metaboliques, Departement de Medecine, CHU Sart Tilman, Liege
    Rev Med Liege 60:814-9. 2005
    ....
  18. ncbi Continuous glucose monitoring reduces both hypoglycaemia and HbA1c in hypoglycaemia-prone type 1 diabetic patients treated with a portable pump
    R P Radermecker
    Division of Diabetes, Nutrition and Metabolic Disorders, CHU de Liege, University of Liege, CHU Sart Tilman, Batiment B35, 4000 Liege, Belgium
    Diabetes Metab 36:409-13. 2010
    ....
  19. ncbi [Prevention of hypoglycemia in patients with type 1 diabetes]
    R P Radermecker
    Service de Diabetologie, Nutrition et Maladies Metaboliques, CHU Sart Tilman, Liege
    Rev Med Liege 58:361-8. 2003
    ..There is no doubt that patient's education plays a crucial role in such a strategy that aims at preventing severe hypoglycaemia in type 1 diabetic individuals...
  20. ncbi [Hypoglycaemic coma, a feared paroxysmal phenomenon in type 1 diabetic patient]
    R P Radermecker
    Service de Diabetologie, Nutrition et Maladies Metaboliques, CHU Sart Tilman, Liege
    Rev Med Liege 59:265-9. 2004
    ..These elements should help to better understand why a hypoglycaemic coma may suddenly occur in a diabetic patient. Some advices will also be given to reduce the risk of such a paroxysmal complication in patients with type 1 diabetes...
  21. ncbi Management of blood glucose in patients with stroke
    R P Radermecker
    Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman, University of Liege, Liege, Belgium
    Diabetes Metab 36:S94-9. 2010
    ....
  22. ncbi [Therapeutic education and continuous glucose monitoring in insulin-treated diabetic patients]
    Vincianne Thielen
    Service de Diabetologie, Nutrition et Maladies Metaboliques, Departement de Medecine, CHU Sart Tilman, Liege, Belgique
    Rev Med Suisse 6:1596-600. 2010
    ..These promising results justify the initiation of larger studies evaluating glucose sensor use in well selected diabetic patients...
  23. ncbi [Hereditary hemochromatosis and diabetes mellitus: diagnostic approach and clinical evolution]
    V Thielen
    , , , CHU Sart Tilman,
    Rev Med Liege 60:448-54. 2005
    ..If diagnosis occurs later, when the patient already needs insulin therapy, diabetes will not be improved by phlebotomy anymore...
  24. ncbi [Drug of the month. Ezetimibe/simvastatin tablet (Inegy)]
    A J Scheen
    Universite de Liege, Departement de Medecine, CHU Sart Tilman, Liege, Belgique
    Rev Med Liege 62:585-90. 2007
    ..Ongoing trials aim at proving the efficacy of such a fixed combination in reducing cardiovascular morbidity and mortality...
  25. ncbi [Blood glucose control and cardiovascular disease in patients with type 2 diabetes. Results of ACCORD, ADVANCE and VA-Diabetes trials]
    R P Radermecker
    CHU Sart Tilman, Liege
    Rev Med Liege 63:511-8. 2008
    ..The best way to protect type 2 diabetic patients against coronary and cerebrovascular disease is to target all cardiovascular risk factors...
  26. ncbi [How I explore...glycemic kinetics by continuous glucose monitoring]
    R P Radermecker
    , , CHU Sart-Tilman,
    Rev Med Liege 58:164-7. 2003
    ....
  27. ncbi [Optimisation of pharmacological therapy in a patient with a newly diagnosed type 2 diabetes]
    J De Flines
    Universite de Liege, Belgique
    Rev Med Liege 64:109-14. 2009
    ....
  28. ncbi [Effects of intensive insulin therapy after an acute myocardial infarction in patients with type 2 diabetes: results of the DIGAMI-2 trial]
    A J Scheen
    , , , CHU Sart Tilman,
    Rev Med Liege 59:534-9. 2004
    ....
  29. ncbi [Incretin mimetics and incretin enhancers for the treatment of type 2 diabetes]
    A J Scheen
    Service de Diabetologie, Nutrition et Maladies métaboliques et Unité de Pharmacologie clinique, CHU Sart Tilman, B 4000 Liege
    Rev Med Suisse 3:1884, 1886-8. 2007
    ..These new drugs offer improved blood glucose control of type 2 diabetic patients, without inducing hypoglycaemia and with favourable effects on body weight...
  30. ncbi [Therapy of type 2 diabetes: between insulin sensitizers and insulin secreting agents]
    A J Scheen
    Universite de Liege, Belgique
    Rev Med Liege 62:40-6. 2007
    ..A global approach should be recommended to reduce the high cardiovascular risk of diabetic patients. The present article aims at summarizing our contribution to the development of drugs designed for the treatment of type 2 diabetes...
  31. ncbi [Strategies avoiding inertia and non compliance in clinical trials]
    B J Jandrain
    Unité de Pharmacologie clinique ATC, CHU de Liege, Belgique
    Rev Med Liege 65:246-9. 2010
    ..Self-monitoring and patient's empowerment in the treatment also contribute to improve drug compliance. Clinicians may take advantage of these approaches derived from clinical trials to improve their daily practice...
  32. ncbi [How to optimize lipid-lowering therapy: do not forget patient's non-compliance]
    R P Radermecker
    Universite de Liege, Service de Diabetologie, Nutrition et Maladies métaboliques et Unite de Pharmacologie, Belgique
    Rev Med Liege 65:311-7. 2010
    ..This article analyses first the main reasons explaining the poor compliance to lipid-lowering therapy and, then, describes some approaches to improve patient's adherence to medications in order to better prevent cardiovascular diseases...
  33. ncbi [Statin for the brain: update in 2008]
    A J Scheen
    Service de Diabetologie, Nutrition et Maladies métaboliques et Unité de Pharmacologie clinique, CHU Sart Tilman, Liege, Belgique
    Rev Med Liege 63:287-92. 2008
    ..Several ongoing trials should confirm or not confirm this new potential indication of statins in a near future...